Emblem (TSXV:EMC, OTC:EMMBF) (“Emblem” or the “Company”) today announced the launch of its first adult-use cannabis brand, Symbl. Leveraging Emblem’s existing brand strength in the medical market, Symbl was created to offer an equally thoughtful brand experience for those seeking cannabis for recreational use that fits within their productive lifestyle.
Symbl was carefully crafted to be an approachable brand for Canadians as they navigate the new cannabis landscape come legalization on October 17, 2018. The brand will break through with a simple mission to inspire curiosity.
“Symbl aims to provoke Canadians’ curiosity – we want to help them uncover new perspectives,” said Maria Guest, Chief Marketing Officer, Emblem. “We understand that there is a learning curve that comes with cannabis legalization, and Symbl is committed to connecting with Canadians on this front to act as a trusted go-to source for brand and product education. This is an evolving and growing sector and our priority will be to keep the dialogue open as Canadians learn more about legal cannabis.”
The launch of Symbl kicks off with the “Get Curious” campaign that champions the spirit of purposeful curiosity. The sentiment behind “Get Curious” is to complement Canadians’ growing interest in learning about cannabis and help them discover the unique properties of cannabis. Through brand activities and experiences, Symbl will engage consumers on this new journey.
Tailored to meet the needs of both novice and seasoned consumers, Symbl will offer a curated selection of signature cannabis products in both dried flower and oil formats. Symbl cannabis is carefully grown and cultivated to ensure a quality experience.
Symbl and Emblem
Known for its ongoing commitment to product innovation and serving customers’ needs, Emblem’s first adult-use brand launch is a natural next step to further connect with Canadians and expand its portfolio.
“Symbl is a natural and symbiotic evolution of the Emblem brand into the adult-use space. Emblem is first and foremost a health and wellness company and we continue to maintain this steadfast focus as we enter the recreational market,” said Nick Dean, CEO, Emblem Corp.
Curious for more? Symbl is now live across major social media channels including Instagram @SymblCannabis; Twitter @SymblCannabis; and Facebook /SymblCanada
Upon legalization for adult-use, Symbl will offer a range of select strains in both flower and oil formats. The line will cater to the full spectrum of Canadians who plan to explore cannabis with products that address individual needs and support a positive and healthy cannabis experience. Symbl is the first brand in the adult-use cannabis division of Emblem. More information is available at www.symbl.ca.
Emblem, through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Emblem’s state-of-the-art indoor cannabis cultivation facility and research and development laboratory is located in Paris, Ontario. Led by an experienced management team of healthcare executives, accomplished marketing professionals, and cannabis experts, Emblem is focused on driving shareholder value through product innovation, brand relevance, and access to patient and consumer channels. Emblem is also the parent company of GrowWise Health Limited, one of Canada’s leading cannabis education services. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.
For media requests, please contact:
Chief Marketing Officer
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “achieve”, “could”, “believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”, “estimate”, “outlook”, “expect”, “may”, “will”, “project”, “should” or similar words, including negatives thereof, suggesting future outcomes. Management of the Company believes the expectations reflected in such forward-looking statements are reasonable as of the date hereof but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. Various material factors and assumptions are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Those material factors and assumptions are based on information currently available to the Company, including data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which Emblem believes to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. While Emblem is not aware of any misstatement regarding any industry or government data presented herein, the medical and adult-use marijuana industry involves risks and uncertainties and is subject to change based on various factors.
Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company’s December 31, 2017 Management’s Discussion and Analysis, which has been filed with the Canadian Securities Administrators and available on www.sedar.com. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Photos accompanying this announcement are available at
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).